Palonosetron
- Generic Name
- Palonosetron
- Brand Names
- Akynzeo, Aloxi, Palonosetron Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C19H24N2O
- CAS Number
- 135729-56-5
- Unique Ingredient Identifier
- 5D06587D6R
- Background
Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is...
- Indication
For the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, as well as prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy. Also used for the prevention of postoperative nausea and vomiting for up to 24 hours post operation.
- Associated Conditions
- Nausea caused by Chemotherapy, Post Operative Nausea and Vomiting (PONV), Acute chemotherapy-induced nausea and vomiting, Delayed chemotherapy-induced nausea and vomiting
- Associated Therapies
- -
Multi-day Doses in Prevention of Nausea and Emesis
- Conditions
- Interventions
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT00600353
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
Safety and Efficacy of Palonosetron in Preventing Chemotherapy-induced Nausea and Vomiting
- Conditions
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2010-09-17
- Lead Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
- Target Recruit Count
- 144
- Registration Number
- NCT00503386
- Locations
- 🇨🇳
Fujian Provincial Tumor Hospital, Fuzhou, Fujian, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Jiangsu Provincial Tumor Hospital, Nanjing, Jiangsu, China
AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors
- Conditions
- Interventions
- First Posted Date
- 2006-12-22
- Last Posted Date
- 2009-09-18
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 196
- Registration Number
- NCT00415103
- Locations
- 🇪🇸
Hospital Universitario La Paz, Madrid, Spain
🇪🇸Hospital Universitario Marqués de Valdecilla, Santander, Spain
🇪🇸Hospital Universitario la Princesa, Madrid, Spain
Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2012-05-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00412425
- Locations
- 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States
Comparative Study of Palonosetron With Granisetron as a Control in Patients Receiving Highly Emetogenic Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2011-07-07
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1140
- Registration Number
- NCT00359567
- Locations
- 🇯🇵
National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan
Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.
- First Posted Date
- 2006-03-24
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT00306735
- Locations
- 🇺🇸
Indiana Blood and Marrow Transplantation, Beech Grove, Indiana, United States
🇺🇸Cornell Medical Center, New York, New York, United States
🇺🇸Wake Forest Medical Center, Winston-Salem, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.